olmutinib investigational anticancer drug acts covalently bonding cysteine residue near kinase domain epidermal growth factor receptor us given breakthrough therapy designation nonsmall cell lung cancer nsclc december south korea drug approved may secondline treatment nsclc mutation resistance olmutinib reported persons cancer started progressing developed mutation olmutinib discovered hanmi pharmaceutical licensed boehringer ingelheim agreement million front payment million november hanmi granted exclusive license sell olmutinib china chinese company zai september korean regulatory authorities issued safety alert olmutinib described two cases toxic epidermal necrolysis one fatal case syndrome boeheringer announced termination deal hanmi day citing decision came review available clinical data drug also referring competing antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikiolmutinib